CAS NO. |
Products Name |
180977-44-0 |
GGTI298 |
more... |
GGTI298 is a CAAZ peptidomimetic geranylgeranyltransferase I (GGTase I) inhibitor, strongly inhibiting the processing of geranylgeranylated Rap1A with little effect on processing of farnesylated Ha-Ras, with IC50 values of 3 and > 10 μM, respectively. |
|
1210416-52-6 |
LGH447 |
more... |
PIM447 is novel pan-PIM kinase inhibitor, including Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase. |
|
923978-27-2 |
Elafibranor (GFT505) |
more... |
Elafibranor (GFT505) is an agonist of the peroxisome proliferator-activated receptor(PPAR)-α and -δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. |
|
|
1675203-84-5 |
PD-L1 inhibitor 1 |
more... |
BMS-202 is a inhibitor of the PD-1 (Programmed death- 1) /PD-Ll (Programmed death-ligand 1) protein/protein interaction, extracted from patent WO/2015034820 A1, compound example 202. |
|
956697-53-3 |
NVP-LDE225 |
more... |
LDE225 (NVP-LDE225; Erismodegib) is a Smoothened (Smo) antagonist, inhibiting Hedgehog (Hh) signaling with IC50 of 1.3 nM (mouse) and 2.5 nM (human), respectively. |
|
733030-01-8 |
TAS-102 |
more... |
TAS-102 is a novel oral combination drug that consists of an antineoplastic thymidine-based nucleoside analog, trifluorothymidine, and a potent thymidine phosphorylase inhibitor, tipiracil, in a 1:0.5 molar ratio. |
|
|
1234563-16-6 |
Epetraborole hydrochloride |
more... |
Epetraborole hydrochloride is a novel leucyl-tRNA synthetase (LeuRS) inhibitor, which inhibits protein synthesis by binding "to the terminal adenosine ribose (A76) of leucyl-tRNA synthetase". It is intended for the treatment of infections caused by Gram-negative bacteria. |
|
1883429-22-8 |
BI-9564 |
more... |
BI-9564 is a selective, and cell-permeable BRD9 BD inhibitor, with Kd of 5.9 nM for BRD9, and IC50 of > 100 μM for BET family. |
|
1224887-10-8 |
GSK2256098 |
more... |
GSK2256098 is a selective FAK kinase inhibitor, which inhibits growth and survival of pancreatic ductal adenocarcinoma cells. |
|
|